Claritin Sales Grow For Schering-Plough Despite Zyrtec OTC Competition
This article was originally published in The Tan Sheet
Executive Summary
OTC Claritin sales advanced almost 10 percent in Schering-Plough's fiscal 2008 first quarter despite the "aggressive launch" of Johnson & Johnson's OTC Zyrtec, S-P says
You may also be interested in...
Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows
Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J
Schering-Plough Cutbacks Underscore Consumer Business Importance
Schering-Plough will look to the diversity of its business with strong OTC and animal health divisions to help weather a major company restructuring that will cut roughly 5,500 jobs and achieve $1.5 billion in cost savings by 2012
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.